Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0278488 (metastatic breast cancer)
 7,812 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Cancer patients receiving chemotherapy have an increased risk of developing cardiovascular complications even if they have normal hearts, and the risk is greater if there is known history of heart disease. Various clinical cardiac complications that have been reported are arrhythmias, cardiomyopathy, vaso-occlusion or vasospasm resulting in angina or myocardial infarction. It is well know that cardiovascular complications in oncology patients is caused by anthracyclines. The trastuzumab as the new treatment option for the metastatic breast cancer may be associated with the development of a clinically significant cardiotoxicity. We described and reviewed the cardiotoxicity in oncology patients.
 ...
PMID:[Cardiovascular complications in oncology patients]. 1280 47

An 85-year-old woman suffering from an angina attack was admitted to our hospital, and diagnosed with multiple lung metastases by CT scan. Because she was extremely aged with a long disease-free period of over 12 years, and without any life-threatening state despite multiple lung metastases, she received hormonal therapy. Examestane was considered one of the most-effective hormonal drugs for metastatic breast cancer. The efficacy of the treatment was definite: the multiple metastatic lesions showed a partial response after 5 months'treatment, and reached a complete response after 10 months'treatment. After 8 months in the complete response state, CT scan revealed progressive disease. Fortunately, the lung metastatic lesions were only slowly progressive, and she has no symptoms now. There was no side effect except for complication of subdural hematoma. Examestane is considered highly effective for metastatic breast cancer and well tolerated by an aged patient like this case.
 ...
PMID:[A case of aged recurrent breast cancer with multiple lung metastases responding to examestane monotherapy]. 1653 19